Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
about
Major clinical research advances in gynecologic cancer in 2013Management of relapsed ovarian cancer: a reviewTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsProfile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectivesCritical appraisal of bevacizumab in the treatment of ovarian cancerEffect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive MicroenvironmentBevacizumab in ovarian cancer: A critical review of phase III studiesComparison of three longitudinal analysis models for the health-related quality of life in oncology: a simulation study.Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysisNew ways to successfully target tumor vasculature in ovarian cancer.SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm.Targeting the tumour microenvironment in ovarian cancerSelf-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.Efficacy and toxicity of bevacizumab in recurrent ovarian disease: an update meta-analysis on phase III trials.Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.Bevacizumab: a review of its use in advanced cancer.Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).An overview of early investigational therapies for chemoresistant ovarian cancer.Pazopanib in ovarian cancer.Classical VEGF, Notch and Ang signalling in cancer angiogenesis, alternative approaches and future directions (Review).Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy.Current and emerging treatment options in the management of advanced ovarian cancer.Targeted agents and combinations in ovarian cancer: where are we now?Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.Recurrent ovarian cancer.Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist).Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.The Role of Angiogenesis in the Persistence of Chemoresistance in Epithelial Ovarian Cancer.Applying the Longitudinal Model from Item Response Theory to Assess Health-Related Quality of Life in the PRODIGE 4/ACCORD 11 Randomized Trial.Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer.Targeted therapy of ovarian cancer including immune check point inhibitor.Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?Breaking down the evidence for bevacizumab in ovarian cancer.Systemic therapy for recurrent epithelial ovarian cancer: a clinical practice guideline.
P2860
Q24562146-EB6DE204-51F7-4D1C-B7C0-27A46BC5539CQ26741755-3FEFFAF9-8F01-46FC-B7FE-0EE40B2D3F9CQ26750649-63F423B1-03BB-482B-863C-07DF1F6C5F92Q26751280-BAE77E8F-7C34-48D9-B3C2-0C35B9073C65Q26830403-EA1E64BA-9A9D-472F-97F9-9ACEA44CACE1Q26864045-B104389F-474A-410F-9BBA-4E98540CE1A6Q28076188-5221A769-F967-4DE5-B4D0-B11B12C1C80FQ35079333-C06046BE-4AEA-45E2-BC63-ABF216E7B322Q35595719-19AE40F5-BA82-4246-A670-D6F7A55E6279Q35920527-1BDC1B16-97CE-4BE0-B040-8A4862A4B36DQ35928220-6DAA6551-37E2-4B15-9455-5EDD41E69006Q36424039-5C8B7ABF-8698-4EE9-843E-FCA567BB0F57Q36626921-ACC1800E-83B8-43DA-AC3A-C5788CF12A54Q36719740-8D5B82D6-BEB4-4700-BD20-DF9E887B9094Q36867341-83982EDE-FEAA-4352-B230-9106C2F2D16FQ37022434-9F835F93-E945-4985-9ECF-01EB99FF65E9Q37092780-6AC287C8-EFD9-4C7F-9121-C14896F154EEQ37158437-771D4923-A2F9-4CA8-A9E8-6F1752BE1136Q38260176-94846444-725A-497A-A97E-A89C620FB48FQ38394240-0818D3AE-10A7-4D1B-97DD-3459A870EAB1Q38553247-69686572-D3B1-4534-8F22-42DE4FB3EE09Q38571120-03912DC0-4424-4205-B1AA-8BDB466F8C48Q38645097-5944407D-06E3-46DA-8C25-4E7EE8ACD16FQ38736093-5F4D91FA-C26F-47E8-85FD-1708586773C2Q38751236-C03D281A-A901-447E-A765-A267FC881311Q38760610-B5D91438-3263-47D0-B159-D04230C6453DQ38854993-696C70D6-FFDF-4A1C-B8DE-B4673BA23389Q38872226-CECAAE7E-7AAB-4AC0-BD8C-1918908031D7Q38872230-C912B275-33A5-4D87-92B5-47542B9FA567Q38879397-B06B960F-81DC-44F2-AB53-3A825EC37688Q39001743-43219E01-09F6-4074-9FFF-2463A8EE26C3Q39608246-C5A59B41-7957-4EAC-B58A-0C7AAEB45546Q39815570-FD7B0FBB-9CBD-404A-B32B-E649C0A0BE10Q40195435-FCAE4138-637B-44CC-B5E5-A9CE7990B445Q40270232-7115F7C9-18AE-43AA-9309-114725029300Q41607677-8F4C4095-BB1D-4607-8D3E-FA4265403B6CQ41660578-9F19064F-80E0-4315-A8D9-65CCCE933DF3Q42406072-98A9402C-FA7B-46F8-9565-8C22CA7621D1Q43135873-BE160DC8-2754-45FC-82AE-7A7AA17F837BQ47096976-1E0ADF03-E08C-4145-8695-8438CB2B3AAF
P2860
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Patient-reported outcome resul ...... inum-resistant ovarian cancer.
@en
type
label
Patient-reported outcome resul ...... inum-resistant ovarian cancer.
@en
prefLabel
Patient-reported outcome resul ...... inum-resistant ovarian cancer.
@en
P2093
P2860
P921
P356
P1476
Patient-reported outcome resul ...... tinum-resistant ovarian cancer
@en
P2093
Eric Pujade-Lauraine
Felix Hilpert
Gill Hales
José Angel Arranz
Lari Wenzel
Madeleine T King
Mansoor Raza Mirza
Martin R Stockler
Michael Friedlander
Nikolaus de Gregorio
P2860
P304
P356
10.1200/JCO.2013.51.4240
P407
P577
2014-03-31T00:00:00Z